Role of intraocular steroids for the treatment of diabetic macular edema

Bryan Propes, David Poon, Diana V Do

Research output: Contribution to journalReview article

Abstract

Diabetic macular edema (DME) is a common and treatable cause of moderate vision loss. Since the introduction of focal/grid photocoagulation more than two decades ago, clinicians have been searching for alternative means to prevent further vision loss or improve the vision in eyes with DME, yet laser photocoagulation remains the standard of care. The most widely employed alternative treatment for DME has been the use of intravitreal corticosteroids. Although steroids can reduce the retinal thickening associated with DME, they are associated with adverse side effects such as elevated intraocular pressure and progression of cataract. Recently, a Phase III randomized clinical trial has shown that laser photocoagulation is superior to monotherapy with a preservative-free intravitreal steroid for the treatment of DME for 24 months. Depot steroid preparations, as well as combination therapy of steroid plus laser photocoagulation, are currently being investigated for the treatment of DME.

Original languageEnglish (US)
Pages (from-to)387-393
Number of pages7
JournalExpert Review of Ophthalmology
Volume4
Issue number4
DOIs
StatePublished - Sep 15 2009

Fingerprint

Macular Edema
Light Coagulation
Steroids
Lasers
Therapeutics
Delayed-Action Preparations
Phase III Clinical Trials
Standard of Care
Intraocular Pressure
Cataract
Adrenal Cortex Hormones
Randomized Controlled Trials

Keywords

  • Diabetic macular edema
  • Grid photocoagulation
  • Intravitreal steroid
  • Triamcinolone

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

Role of intraocular steroids for the treatment of diabetic macular edema. / Propes, Bryan; Poon, David; Do, Diana V.

In: Expert Review of Ophthalmology, Vol. 4, No. 4, 15.09.2009, p. 387-393.

Research output: Contribution to journalReview article

Propes, Bryan ; Poon, David ; Do, Diana V. / Role of intraocular steroids for the treatment of diabetic macular edema. In: Expert Review of Ophthalmology. 2009 ; Vol. 4, No. 4. pp. 387-393.
@article{c435664875994f48b399902f71c01952,
title = "Role of intraocular steroids for the treatment of diabetic macular edema",
abstract = "Diabetic macular edema (DME) is a common and treatable cause of moderate vision loss. Since the introduction of focal/grid photocoagulation more than two decades ago, clinicians have been searching for alternative means to prevent further vision loss or improve the vision in eyes with DME, yet laser photocoagulation remains the standard of care. The most widely employed alternative treatment for DME has been the use of intravitreal corticosteroids. Although steroids can reduce the retinal thickening associated with DME, they are associated with adverse side effects such as elevated intraocular pressure and progression of cataract. Recently, a Phase III randomized clinical trial has shown that laser photocoagulation is superior to monotherapy with a preservative-free intravitreal steroid for the treatment of DME for 24 months. Depot steroid preparations, as well as combination therapy of steroid plus laser photocoagulation, are currently being investigated for the treatment of DME.",
keywords = "Diabetic macular edema, Grid photocoagulation, Intravitreal steroid, Triamcinolone",
author = "Bryan Propes and David Poon and Do, {Diana V}",
year = "2009",
month = "9",
day = "15",
doi = "10.1586/eop.09.30",
language = "English (US)",
volume = "4",
pages = "387--393",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
number = "4",

}

TY - JOUR

T1 - Role of intraocular steroids for the treatment of diabetic macular edema

AU - Propes, Bryan

AU - Poon, David

AU - Do, Diana V

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Diabetic macular edema (DME) is a common and treatable cause of moderate vision loss. Since the introduction of focal/grid photocoagulation more than two decades ago, clinicians have been searching for alternative means to prevent further vision loss or improve the vision in eyes with DME, yet laser photocoagulation remains the standard of care. The most widely employed alternative treatment for DME has been the use of intravitreal corticosteroids. Although steroids can reduce the retinal thickening associated with DME, they are associated with adverse side effects such as elevated intraocular pressure and progression of cataract. Recently, a Phase III randomized clinical trial has shown that laser photocoagulation is superior to monotherapy with a preservative-free intravitreal steroid for the treatment of DME for 24 months. Depot steroid preparations, as well as combination therapy of steroid plus laser photocoagulation, are currently being investigated for the treatment of DME.

AB - Diabetic macular edema (DME) is a common and treatable cause of moderate vision loss. Since the introduction of focal/grid photocoagulation more than two decades ago, clinicians have been searching for alternative means to prevent further vision loss or improve the vision in eyes with DME, yet laser photocoagulation remains the standard of care. The most widely employed alternative treatment for DME has been the use of intravitreal corticosteroids. Although steroids can reduce the retinal thickening associated with DME, they are associated with adverse side effects such as elevated intraocular pressure and progression of cataract. Recently, a Phase III randomized clinical trial has shown that laser photocoagulation is superior to monotherapy with a preservative-free intravitreal steroid for the treatment of DME for 24 months. Depot steroid preparations, as well as combination therapy of steroid plus laser photocoagulation, are currently being investigated for the treatment of DME.

KW - Diabetic macular edema

KW - Grid photocoagulation

KW - Intravitreal steroid

KW - Triamcinolone

UR - http://www.scopus.com/inward/record.url?scp=70049117168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70049117168&partnerID=8YFLogxK

U2 - 10.1586/eop.09.30

DO - 10.1586/eop.09.30

M3 - Review article

VL - 4

SP - 387

EP - 393

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

SN - 1746-9899

IS - 4

ER -